Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Fujifilm To Enter Radiopharmaceuticals

by Michael McCoy
November 10, 2014 | A version of this story appeared in Volume 92, Issue 45

Fujifilm will spend more than $50 million to enter the market for positron emission tomography (PET) radiopharmaceuticals used in disease diagnosis. The Japanese firm will use the money to establish labs in Ibaraki City and Kawasaki City, Japan, where it will research radiolabeled compounds that can help diagnose Alzheimer’s and other diseases. Last month Fujifilm agreed to help Eli Lilly & Co. win Japanese approval for florbetapir, which is approved in the U.S. to detect brain plaques associated with Alzheimer’s.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.